Comparative Pharmacology
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus FAZACLO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus FAZACLO ODT.
DAPIPRAZOLE HYDROCHLORIDE vs FAZACLO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
Clozapine is an atypical antipsychotic that antagonizes serotonin 5-HT2A and dopamine D2 receptors, with higher affinity for 5-HT2A. It also blocks muscarinic M1, histaminergic H1, and adrenergic α1 and α2 receptors.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
Clozapine (FAZACLO ODT) is an atypical antipsychotic. For schizophrenia, the typical starting dose is 12.5 mg orally once daily or twice daily, titrated by 25-50 mg/day to a target dose of 300-450 mg/day divided, up to a maximum of 900 mg/day. For treatment-resistant schizophrenia, the target dose is 300-450 mg/day, with doses above 500 mg/day requiring slower titration. The oral disintegrating tablet is taken sublingually or swallowed whole.
None Documented
None Documented
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Terminal elimination half-life: 14 hours (range 6-26 hours) at steady state; increases with dose/duration. Context: Twice-daily dosing achieves steady state in 5-7 days.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Renal: 50% as metabolites (30% conjugated, 20% desmethylclozapine), 30% as unchanged; Fecal: 30% (biliary/fecal elimination of metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic